{"id":9767,"date":"2025-09-24T00:33:28","date_gmt":"2025-09-23T22:33:28","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/"},"modified":"2025-09-24T00:33:29","modified_gmt":"2025-09-23T22:33:29","slug":"letude-multi-inscription-met-en-evidence","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/","title":{"rendered":"L&rsquo;\u00e9tude multi-inscription met en \u00e9vidence"},"content":{"rendered":"<div>\n<div class=\"article-gallery lightGallery\">\n<div data-thumb=\"https:\/\/scx1.b-cdn.net\/csz\/news\/tmb\/2023\/multiple-sclerosis-1.jpg\" data-src=\"https:\/\/scx2.b-cdn.net\/gfx\/news\/hires\/2023\/multiple-sclerosis-1.jpg\" data-sub-html=\"Credit: Unsplash\/CC0 Public Domain\">\n<figure class=\"article-img\">\n<\/figure><\/div>\n<\/div>\n<p>De nouvelles recherches pr\u00e9sent\u00e9es au 41e Congr\u00e8s du Comit\u00e9 europ\u00e9en pour le traitement et la recherche dans la scl\u00e9rose en plaques (Ectrims 2025) d\u00e9montrent que l&rsquo;ocr\u00e9lizumab fournit un contr\u00f4le sup\u00e9rieur de la scl\u00e9rose en plaques (SEP) rechut par rapport au fingolimod, au natalizumab et \u00e0 l&rsquo;alemtuzumab.<\/p>\n<p>Ocrelizumab, un anticorps monoclonal ciblant les cellules CD20 + B, a \u00e9t\u00e9 \u00e9valu\u00e9 \u00e0 l&rsquo;aide de donn\u00e9es r\u00e9elles de trois grands registres MS: MSBase, OFSEP et le registre danois MS. L&rsquo;analyse a compar\u00e9 des patients trait\u00e9s par Ocrelizumab avec des cohortes recevant du fingolimod (2 600 contre 4 103 patients), du natalizumab (3 197 contre 2 437 patients) et de l&rsquo;alemtuzumab (2 960 contre 644 patients), tous avec au moins six mois de traitement et de suivi.<\/p>\n<p>Dans la comparaison du fingolimod, les taux de rechute MS \u00e9taient significativement plus faibles avec l&rsquo;ocr\u00e9lizumab (0,06 contre 0,14; p <0,001). Les patients atteints de fingolimod avaient plus du double du risque de rechute (HR 2,26, IC \u00e0 95% 1,98\u20132,58), un risque plus \u00e9lev\u00e9 d'aggravation associ\u00e9e \u00e0 la rechute et une plus faible probabilit\u00e9 d'am\u00e9lioration de l'invalidit\u00e9.<\/p>\n<p>Compar\u00e9 au natalizumab et \u00e0 l&rsquo;alemtuzumab, l&rsquo;ocr\u00e9lizumab a \u00e9galement montr\u00e9 des taux de rechute plus faibles (0,07 contre 0,10 et 0,12 contre 0,18, respectivement; les deux p <0,001). De plus, l'ocr\u00e9lizumab a r\u00e9duit le risque d'aggravation associ\u00e9e \u00e0 la rechute par rapport au natalizumab, alors qu'aucune diff\u00e9rence de ce type n'a \u00e9t\u00e9 observ\u00e9e par rapport \u00e0 l'alemtuzumab.<\/p>\n<p>Le Dr Izanne Roos, auteur principal de l&rsquo;\u00e9tude, a d\u00e9clar\u00e9: \u00ab\u00a0Bien que les diff\u00e9rences entre l&rsquo;ocr\u00e9lizumab et le natalizumab ou l&rsquo;alemtuzumab soient statistiquement significatives, ils \u00e9taient modestes. Par exemple, il y avait environ un rechute de moins pour 33 ann\u00e9es de patient lors de la comparaison du natalizumab \u00e0 l&rsquo;activit\u00e9 de la maladie r\u00e9cente. na\u00eff.\u00a0\u00bb<\/p>\n<p>Les donn\u00e9es sur les \u00e9v\u00e9nements ind\u00e9sirables n&rsquo;\u00e9taient pas syst\u00e9matiquement disponibles dans tous les registres. En tant que proxy de tol\u00e9rabilit\u00e9, l&rsquo;\u00e9tude a examin\u00e9 la persistance du traitement. Seuls 8% des patients natalizumab et 6% des patients ocr\u00e9lizumabs ont interrompu le traitement en raison d&rsquo;une mauvaise tol\u00e9rabilit\u00e9, ce qui sugg\u00e8re que les deux th\u00e9rapies sont g\u00e9n\u00e9ralement bien tol\u00e9r\u00e9es.<\/p>\n<p>Bien que l&rsquo;ocr\u00e9lizumab r\u00e9duit syst\u00e9matiquement les rechutes et l&rsquo;aggravation associ\u00e9e \u00e0 la rechute, il n&rsquo;y avait aucune preuve de diff\u00e9rences de progression ind\u00e9pendantes de l&rsquo;activit\u00e9 de la rechute ou de l&rsquo;am\u00e9lioration de l&rsquo;invalidit\u00e9 par rapport aux autres th\u00e9rapies \u00e0 haute efficacit\u00e9.<\/p>\n<p>\u00ab\u00a0Ces r\u00e9sultats sugg\u00e8rent que nous avons peut-\u00eatre atteint le plafond de b\u00e9n\u00e9fice d&rsquo;invalidit\u00e9 r\u00e9alisable via la suppression des rechutes seuls, mettant en \u00e9vidence le besoin urgent de traitements qui ciblent la progression ind\u00e9pendante des rechutes\u00a0\u00bb, a conclu le Dr Roos.<\/p>\n<p>\t\t\t\t\t\t\t\t\t\t\t\tFourni par le Comit\u00e9 europ\u00e9en pour le traitement et la recherche sur la scl\u00e9rose en plaques<\/p>\n<p>                                        <!-- print only --><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>De nouvelles recherches pr\u00e9sent\u00e9es au 41e Congr\u00e8s du Comit\u00e9 europ\u00e9en pour le traitement et la<\/p>\n","protected":false},"author":1,"featured_media":8372,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[1403,1346,815,6769],"class_list":["post-9767","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-evidence","tag-letude","tag-met","tag-multiinscription","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>L&#039;\u00e9tude multi-inscription met en \u00e9vidence - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;\u00e9tude multi-inscription met en \u00e9vidence - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"De nouvelles recherches pr\u00e9sent\u00e9es au 41e Congr\u00e8s du Comit\u00e9 europ\u00e9en pour le traitement et la\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T22:33:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T22:33:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"L&rsquo;\u00e9tude multi-inscription met en \u00e9vidence\",\"datePublished\":\"2025-09-23T22:33:28+00:00\",\"dateModified\":\"2025-09-23T22:33:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/\"},\"wordCount\":152,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg\",\"keywords\":[\"\u00e9vidence\",\"L\u00e9tude\",\"met\",\"multiinscription\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/\",\"name\":\"L'\u00e9tude multi-inscription met en \u00e9vidence - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg\",\"datePublished\":\"2025-09-23T22:33:28+00:00\",\"dateModified\":\"2025-09-23T22:33:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"La scl\u00e9rose en plaques peut commencer bien plus t\u00f4t qu'auparavant\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&rsquo;\u00e9tude multi-inscription met en \u00e9vidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'\u00e9tude multi-inscription met en \u00e9vidence - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/","og_locale":"fr_FR","og_type":"article","og_title":"L'\u00e9tude multi-inscription met en \u00e9vidence - RVH-Synergie.org","og_description":"De nouvelles recherches pr\u00e9sent\u00e9es au 41e Congr\u00e8s du Comit\u00e9 europ\u00e9en pour le traitement et la","og_url":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/","og_site_name":"RVH-Synergie","article_published_time":"2025-09-23T22:33:28+00:00","article_modified_time":"2025-09-23T22:33:29+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"L&rsquo;\u00e9tude multi-inscription met en \u00e9vidence","datePublished":"2025-09-23T22:33:28+00:00","dateModified":"2025-09-23T22:33:29+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/"},"wordCount":152,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg","keywords":["\u00e9vidence","L\u00e9tude","met","multiinscription"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/","url":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/","name":"L'\u00e9tude multi-inscription met en \u00e9vidence - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg","datePublished":"2025-09-23T22:33:28+00:00","dateModified":"2025-09-23T22:33:29+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/08\/1754096162_La-sclerose-en-plaques-peut-commencer-bien-plus-tot-quauparavant-scaled.jpg","width":2560,"height":1707,"caption":"La scl\u00e9rose en plaques peut commencer bien plus t\u00f4t qu'auparavant"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/letude-multi-inscription-met-en-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"L&rsquo;\u00e9tude multi-inscription met en \u00e9vidence"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d&#039;informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/9767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=9767"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/9767\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/8372"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=9767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=9767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=9767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}